Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street ...

From left: Eric Keller of Noveome Biotherapeutics, Heidi Wagner of ElevateBio, Krish Krishnan of Krystal Biotech, and Betty Woo of Thermo Fisher Scientific, during the Life Sciences Future PA ...

Rather, with so much uncertainty, investors are prizing biotech companies that base their intellectual property and manufacturing in the U.S., which up until now often meant higher taxes.

His ousting of Peter Marks—a senior official at the Food and Drug Administration and key proponent of faster drug approvals—sent biotech stocks tumbling last month and stoked concerns that the ...

But today, Kendall has been reborn — as the glittering, glassy heart of America’s biotech industry. For many companies, Kendall Square’s status as a global center of biotechnology firms and ...

The antibody is in preclinical development and is expected to enter the clinic next year. The biotech hopes to bring first-in-class therapies to patients impacted by inflammation, autoimmunity and ...

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions.

PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing ...

Ajooni Biotech Limited was originally incorporated as a Private Limited Company with the name Ajooni Biotech Private Limited at Chandigarh on 17th February, 2010. Consequent upon conversion of the ...

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers.

The firm claimed the biotech market has seen a “significant shift” in recent years, leading to scarce investor financing for early-stage biotech firms. Battelle, a nonprofit Columbus-based ...